Dashboard
Manage Tickers

JNJ


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-clears-johnson--johnsons-darzalex-faspro-enabling-early-intervention-in-myeloma-progression
FDA Clears Johnson & Johnson's Darzalex Fa...
11/07/2025 17:57:40

The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on...

fda-fast-tracks-6-more-drugs---obesity-and-cancer-drugs-included
FDA Fast-Tracks 6 More Drugs - Obesity And...
11/07/2025 14:54:21

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescr...

Core News & Articles
Halozyme Therapeutics Announces Johnson & ...
11/07/2025 13:31:58

Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Adm...

Core News & Articles
'Attor­ney Gen­er­al Ken Pax­ton Fights To...
11/06/2025 20:29:13

https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-fights-stop-manufacturer-tylenol-fraudulently-pa...

fda-approves-daratumumab-and-hyaluronidase-fihj-for-high-risk-smoldering-multiple-myeloma
FDA Approves Daratumumab And Hyaluronidase...
11/06/2025 19:52:44

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smolde...

johnson--johnson-announces-fda-approval-of-caplyta-as-adjunctive-therapy-with-antidepressants-to-treat-major-depressive-disorder-in-adults
Johnson & Johnson Announces FDA Approval O...
11/06/2025 12:37:31

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateper...

options-corner-kimberly-clarks-implosion-offers-an-unusual-informational-arbitrage-opportunity
Options Corner: Kimberly-Clark's Implosion...
11/03/2025 20:56:05

Although Kimberly-Clark suffered a huge blow after announcing its Kenvue buyout, KMB stock is flashing a quantitative contraria...

gold-edges-higher-ism-manufacturing-pmi-falls-in-october
Gold Edges Higher; ISM Manufacturing PMI F...
11/03/2025 19:23:45

alvotech-shares-plunge-33-after-fda-flags-issues
Alvotech Shares Plunge 33% After FDA Flags...
11/03/2025 18:17:22

Alvotech shares decline after the FDA issues a complete response letter for its Simponi biosimilar, leading to a lower 2025 rev...

Core News & Articles
Buffett Sells Stocks – Here Is What Pruden...
11/03/2025 16:13:32

Buffett Sells Stocks

kimberly-clark-stock-plunges-over-16-kenvue-surges-20-in-monday-pre-market-whats-going-on
Kimberly-Clark Stock Plunges Over 16%, Ken...
11/03/2025 12:16:56

Shares of Kimberly-Clark Corporation (NASDAQ: KMB) plunged 16.49% during the pre-market trading session on Monday, after it ann...

johnson--johnson-submits-application-to-us-fda-for-stelara-in-the-treatment-of-pediatric-ulcerative-colitis
Johnson & Johnson Submits Application To U...
10/31/2025 20:08:04

https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-u-s-fda-for-stelara-ustekinumab-in-the-t...

eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain
Eli Lilly Extends Lead In $150B Obesity Dr...
10/30/2025 20:04:44

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

johnson--johnson-plans-to-initiate-first-head-to-head-study-comparing-fcrn-blockers-for-patients-with-generalized-myasthenia-gravis
Johnson & Johnson Plans To Initiate First ...
10/29/2025 12:07:04

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch ...

ken-paxton-alleges-johnson--johnson-misled-mothers-on-tylenol-safety
Ken Paxton Alleges Johnson & Johnson Misle...
10/28/2025 17:11:17

Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for ...

Core News & Articles
Johnson & Johnson, Kenvue Sued By Texas At...
10/28/2025 12:53:44

https://www.texasattorneygeneral.gov/news/releases/attorney-general-paxton-sues-big-pharma-manufacturers-deceptively-marketing-...

Core News & Articles
'US Fires Top Health Official Who Opposed ...
10/28/2025 12:50:58

https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...

johnson--johnson-2-year-data-from-encompass-trial-for-tremfya-for-psoriasis-demonstrates-unmet-needs-strong-preference-for-oral-treatment-options
Johnson & Johnson 2-Year Data From ENCOMPA...
10/27/2025 12:14:13

Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating pat...

johnson--johnsons-tremfya-shows-two-year-results-for-crohns-disease-patients-reports-96-week-data-proving-long-term-benefits-of-tremfya-in-crohns-disease
Johnson & Johnson's TREMFYA Shows Two-Year...
10/27/2025 11:39:07

Johnson & Johnson (NYSE:JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, G...

jj-reports-28-week-data-for-experimental-ulcerative-colitis-treatment-icotrokinra
J&J Reports 28-Week Data for Experimental ...
10/27/2025 11:37:39

Johnson & Johnson (NYSE:JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-c...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION